1 report

This is expected – at some point during H## 2015 – to trigger the launch of Celltrion and Hospira' s biosimilar infliximab product, which gained EU approval in September 2013 (as the region' s first biosimilar monoclonal antibody) and which is sold in various other European

  • Biosimilar
  • Medical Biotechnology
  • Monoclonal Antibody
  • Europe
  • Market Description